House Bill 258 Seeks To Force Health Care Providers to Tell Patients If They Have Dense Breast Tissue

Approximately 10 million women have high breast density in the United States and there is currently no FDA-approved treatment for this condition. For more information about breast density please visit www.areyoudense.org

Recently, House Bill 258 advanced to the senate and proposes that health care providers would be required to tell patients if they have dense breast tissue and to consider further cancer screenings.

The proposed notice reads:

“Your mammogram indicates that you have dense breast tissue. Dense breast tissue is common and is found in as many as half of all women.

However, dense breast tissue can make it more difficult to fully and accurately evaluate your mammogram and detect early signs of possible cancer in the breast.

You might benefit from additional professionally recognized forms of cancer screening examinations, depending on your personal risk factors and family history.

This information is being provided to inform and encourage you to discuss your dense breast tissue and other breast cancer risk factors with your physician or health care provider.

Together, you can decide which screening options are best and most effective for you. A copy of your mammography report has been sent to your physician and health care provider.

Please contact them if you have any questions or concerns about this notice.”

 

President and CEO of Seattle, WA based Atossa Genetics (NasdaqCM: ATOS), Dr. Steven Quay, commented on this subject recently, “The presence of dense breast tissue can make it more difficult to evaluate the results of a mammogram because dense breast tissue is comprised of less fat and more stromal tissue which appears white on a mammogram. Cancer also appears white and tumors are therefore often hidden or masked by the dense tissue. Breast density is also associated with an increased risk of breast cancer. Although numerous states have recently enacted laws requiring that patients be notified of breast density, there is no federal standard and approximately 20 states still do not require that information about density be conveyed to the patient. We believe woman have the right to receive this important health information and we applaud the pending federal legislation. In addition, the provisions in the legislation that require expansion of programs and research activities related to breast density should improve diagnosis capabilities and accelerate treatments for this major breast cancer risk factor; which is one of only a few risk factors that can actually be modified.” Atossa is developing the drug Endoxifen for tamoxifen-refractory breast cancer patients, the treatment of mammographic breast density and other breast conditions. Atossa’s proprietary Endoxifen is being developed as an oral form as well as a topical solution, like a lotion, that can be applied directly to the breast. Atossa recently completed a Phase 1 study of its oral and topical Endoxifen and reported that all objectives of that study were successfully met. A Phase 2 study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, M.D., Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.

 

To learn about the interesting work that Seattle, WA based biotech firm Atossa Genetics (NasdaqGM: ATOS) is doing in breast cancer treatment please visit the Vista Partners ATOS Company Dedicated Page.

Bill warning women of dense breast tissue advances to Senate

SALT LAKE CITY, Utah (News4Utah) A house bill advanced to the senate Friday that would require doctors to notify women if a mammogram discovers dense breast tissue…

www.good4utah.com

Read Full Article



HIIQ Reports Record Q4 & Fiscal 2017 Financial & Operating Results

Health Insurance Innovations, Inc. (HIIQ), a leading cloud-based technology platform and distributor of affordable individual and family health insurance and supplemental plans, today announced financial results for the Q4 and year ended December 31, 2017. HIIQ specifically reported the following:

2017 Annual Consolidated Financial Highlights

-Record revenue was $250.5 million, compared to $184.5 million in 2016, an increase of 35.8%.
-Record total collections from members (premium equivalents) of $395.6 million compared to $311.6 million in 2016, an increase of 27.0%.
-Net income was $26.5 million, compared to $13.1 million in 2016, an increase of 102.3%.
-Record adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $45.5 million, compared to $27.8 million in 2016, an increase of 63.7%.
-Record GAAP diluted earnings per share was $1.50, compared to $0.57 in 2016, an increase of 163.2%.
-Record adjusted earnings per share, also referred to as adjusted net income per share, or adjusted EPS, was $1.65 compared to $1.12 in 2016, an increase of 47.3%.
-Record policies in force as of December 31, 2017, totaled approximately 376,100, compared to 290,100 as of December 31, 2016, an increase of 29.6%.
-Cash and cash equivalents totaled $39.3 million as of December 31, 2017, an increase of $27.1 million from December 31, 2016.
-Premium equivalents, adjusted EBITDA, and adjusted EPS are non-GAAP financial measures. See the reconciliations of these measures to their respective most directly comparable GAAP measure below in this press release.

2018 Full Year Guidance

The Company expects annual revenue for 2018 to be between $290 million and $300 million or grow approximately 15% to 20% year-over-year, adjusted EBITDA to be between $54 million and $57 million or grow approximately 20% to 25% year-over-year and adjusted EPS to be between $2.45 and $2.55 or grow approximately 48% to 55% year-over-year. These guidance numbers are based on the Company’s current method of accounting for revenue. As an emerging growth company, it will be adopting the revised revenue recognition standard, known as ASC 606, in the fourth quarter of 2018.

“We continue to efficiently provide affordable healthcare solutions to consumers who would not otherwise have insurance that meets their needs. As we look ahead, we will continue to invest in our technology platform to improve our member’s experience and we will launch the next generation of our technology platform in 2018. We will also continue to invest in ecommerce, enhance our scalability and maintain our competitive advantage,” said Gavin Southwell, HIIQ’s Chief Executive Officer and President.

Fourth Quarter 2017 Consolidated Financial Highlights

-Record revenue was $69.5 million, compared to $51.4 million in the fourth quarter of 2016, an increase of 35.2%.
-Record total collections from members (premium equivalents) of $106.3 million compared to $85.3 million in the fourth quarter of 2016, an increase of 24.6%.
-Net income was $5.0 million, compared to $1.4 million in the fourth quarter of 2016, an increase of 257.1%.
-Record adjusted EBITDA was $10.5 million, compared to $8.9 million in the fourth quarter of 2016, an increase of 18.0%.
-GAAP diluted earnings per share was $0.30, compared to a loss of $0.02 in the fourth quarter of 2016.
-Adjusted EPS, was $0.37 compared to $0.35 in the fourth quarter of 2016, an increase of 5.7%.

2017 Financial Discussion

2017 revenues of $250.5 million increased 35.8%, compared to 2016, driven by an increase in policies in force, favorable commission margins and improved discount benefit plan offerings.

A live earnings conference call will be held on Thursday, March 1, 2017, at 8:30 a.m. Eastern time. To participate in the call, please dial (877) 407-9039 (domestic) or (201) 689-8470 (international). The conference ID is 13675038. The online replay can be accessed using the conference passcode 13675038, on the Investor Relations section of the company’s website at http://investor.hiiquote.com/.

To learn more about HIIQ and to track its ongoing progress please visit the Vista Partners HIIQ Coverage Page.

Health Insurance Innovations, Inc. Reports Record Fourth Quarter and Fiscal 2017 Financial and Operating Results

Record Revenues of $250.5 million, up 35.8% YOY Record GAAP Diluted Earnings per Share of $1.50, up 163.2% YOY Record Adjusted Earnings per Share of $1.65, up 47.3% YOY Record Policies in Force totaled …..

finance.yahoo.com

Read Full Article



Vista Partners Publishes The February 2018 FREE Macroeconomic & Investment Monthly Newsletter

Vista Partners (“Vista”) has published February’s FREE Macroeconomic & Investment Monthly Newsletter, “Clear Skies Ahead?”.

Vista’s monthly newsletter contains investment considerations for Banks, Biotech, Cloud Services, Energy, Fintech, Healthcare, Manufacturing, Materials, Real Estate, SaaS, and Technology.

Vista Partners centers its Coverage on the Dow 30 Components, Select Emerging Growth Companies & Vista’s Featured Companies, with exclusive, broad-based commentary from Managing Director, John F. Heerdink, Jr.

In February’s edition of the Macroeconomic & Investment Newsletter, Mr. Heerdink states, “For anyone holding long-term Treasuries, this could be a nightmare. If we see a move….” Read full newsletter.

Companies Featured in February’s Newsletter: Apple (AAPL), Atossa Genetics, Inc. (NASDAQ: ATOS) | Caterpillar (CAT) | Disney (DIS) | Fusion, Inc. (NASDAQ: FSNN) | & General Mills (GIS).

Vista Partners publishes 100% of its content free. Vista Partners offers a wealth of mixed-media resources on the Dow 30 & Select Emerging Growth Companies. To receive FREE email updates from Vista’s select & extensive coverage universe, please sign up at VistaPGlobal.com/signup.

About Vista Partners LLC:

Founded in 2005, Vista Partners LLC (“Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, and Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.

Please follow Vista Partners on Twitter @VistaPResearch to receive updates, thoughts, and ideas on Dow 30 Components, Select Emerging Growth Companies & Vista’s Featured Companies.

Contact:

inquiries@VistaPGlobal.com




“Back In Order?” Vista Partners’ Weekly Market Update 2-17-18

Vista Partners has published “Back In Order?” Vista Partners Weekly Market Update 2-17-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30 and Select Emerging Growth Companies.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

Stay Informed! Stay Competitive! It’s FREE & EASY to sign up.




Health Insurance Innovations Surges Today & Schedules Earnings Call Feb. 28

Health Insurance Innovations, Inc. (HIIQ), is a market leading distributor and cloud-based administrator of innovative health insurance products that are affordable and meet the needs of health insurance plan shoppers. HIIQ develops insurance products through our relationships with best-in-class insurance companies and markets them via its broad distribution network of licensed insurance agents across the nation, its call center network and its unique online capability.  HIIQ’s Consumer Division includes AgileHealthInsurance.com, a website for researching, comparing and purchasing short-term health insurance products online and HealthPocket.com, a free website that compares and ranks all health insurance plans and uses objective data to publish unbiased health insurance market analyses and other consumer advocacy research.

HIIQ will announce its fourth quarter and year-end 2017 financial and operating results on Wednesday, February 28, 2018, after market close. The announcement will be followed by a live earnings conference call on Thursday, March 1, 2017, at 8:30 a.m. Eastern time. To participate in the call, please dial (877) 407-9039 (domestic) or (201) 689-8470 (international). The conference ID is 13675038. The online replay can be accessed using the conference passcode 13675038, on the Investor Relations section of the company’s website at http://investor.hiiquote.com/.

HIIQ’s stock closed at $31.05 up $4 per share or 14.79% today on 1,555,791 shares of trading.  Many pointed to the increase was attributed to thise specualting around their earnings and HIIQ confirming via SEC filing that the Florida Office Insurance Regulation granted HIIQ’s subsidiary, Health Plan Intermediaries Holdings, LLC, a certificate of authority which allows it to conduct business in FL as a third-party administrator. HIIQ will also pay a $140,000 fine for doing business in the state prior to submitting its application for the certificate fall 2017. HIIQ also the Texas Department of Insurance closed their inquiry  on Feb. 2, 2018, without a violation or disciplinary action.

To learn more about Health Insurance Innovations, Inc. (NasdaqGM: HIIQ) and to track its progress please visit the Vista Partners HIIQ Company Dedicated Coverage Page.

Health Insurance Innovations, Inc. to Announce Fourth Quarter and Year-End 2017 Results on Wednesday, February 28, 2018

TAMPA, Fla., Feb. 15, 2018– Health Insurance Innovations, Inc., a leading distributor and cloud based administrator of affordable health plans, will announce its fourth quarter and year-end 2017 financial …..

finance.yahoo.com

Read Full Article



Vista Partners Updates Coverage on Four Dow 30 Companies: CAT, 3M, IBM & UNH

Vista Partners (“Vista”) has published updated coverage on four Dow 30 components 3M (MMM), Caterpillar (CAT), IBM (IBM) & UnitedHealth Group (UNH).  The reports may be downloaded for FREE at the Vista Partners Coverage Section.

Vista recently published a report on Atossa Genetics (NasdaqCM: ATOS) a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions that announced additional findings from its Phase 1 study of Atossa’s proprietary oral Endoxifen recently.

Shares of Atossa (ATOS) closed up 17.06% today while trading volumes have risen to 4,480,000/day since last week when Vista Partners Published it’s FREE Research Report. DOWNLOAD the Vista Partners FREE Report at http://www.vistapglobal.com/vp-coverage/atossa-genetics-inc-atos/.

Vista also maintains coverage on cloud service provider Fusion (NasdaqCM: FSNN) and affordable health insurance product provider Health Insurance Innovations (NasdaqGM: HIIQ). See Featured Coverage here.

Vista Partners publishes 100% of its content free. Vista Partners offers a wealth of mixed-media resources on the Dow 30 & Select Emerging Growth Companies.

To receive FREE email updates from Vista’s select & extensive coverage universe, please sign up at VistaPGlobal.com/signup.

ABOUT VISTA PARTNERS

Founded in 2005, Vista Partners LLC (“Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, and Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.

Please follow Vista Partners on Twitter @VistaPResearch to receive updates, thoughts, and ideas on Dow 30 Components, Select Emerging Growth Companies & Vista’s Featured Companies.

Contact:

inquiries@VistaPGlobal.com

SOURCE: Vista Partners LLC




It’s Almost Time for San Francisco’s J.P. Morgan Healthcare Conference Week!

J.P. Morgan (NYSE: JMP) launched Wall Street’s premier investor conference focused exclusively on companies defining the healthcare industry 35 Years ago. Today, the J.P. Morgan Healthcare Conference hosts the largest and most informative healthcare investment symposium in the industry. In 2018, J.P. Morgan expects more than 400 companies to deliver presentations to more than 8,000 attendees,  but as impressive as these numbers are they fail in comparison to the much greater number of companies, investors, conferences, partnership meetings & night events that are participating, attending and being held during this same week. Some estimate that nearly 60,000 come into the town to capitalize on and around this event. The event next week is on January 8 – 11, 2018 at the Westin St. Francis in San Francisco’s Union Square. All J.P. Morgan conferences are by invitation only. Invitations are non-transferable.

I have been attending J.P. Morgan Conference Week activities since 1999 and again will be meeting with over 30 companies including a wide range of biotech, med-tech and pharmaceutical companies from private entities to multi-billion dollar public companies in order to further identify trends and seek to capitalize on the growth. It will be exhausting but well worth it.

Specifically, I will further be seeking to gain greater insight on 5 companies that I cover at Vista Partners that include: Breast cancer-focused biotech firm Atossa Genetics (ATOS), Short-term insurance provider Health Insurance Innovations (HIIQ), Pharmaceutical Giants Johnson & Johnson (JNJ), Merck (MRK), & Pfizer (PFE). Please see our Coverage Pages for all and to learn more. Any thoughts, ideas or other companies that we should meet with next week please forward introductions to inquiries@vistapglobal.com.

 




“Is It Time to Toast?” See Vista Partners Weekly Market Update 12-30-17

Vista Partners has published  “Is It Time to Toast?” Vista Partners Weekly Market Update 12-30-17 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30 and Select Emerging Growth Companies.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

Stay Informed! Stay Competitive! It’s FREE & EASY to sign up.

Have a great weekend and a Happy 2018!




“The Bright Lights of 2017” Vista Partners December Macroeconomic & Investment Newsletter 12-28-2017

Vista Partners (“Vista”) has published December’s FREE Macroeconomic & Investment Monthly Newsletter, “The Bright Lights of 2017”.

Vista’s monthly newsletter contains investment considerations for Banks, Biotech, Cloud Services, Energy, Fintech, Healthcare, Manufacturing, Materials, Real Estate, SaaS, and Technology.

Vista Partners centers its Coverage on the Dow 30 Components, Select Emerging Growth Companies & Vista’s Featured Companies, with exclusive, broad-based commentary from Managing Director, John F. Heerdink, Jr.

In December’s edition of the Macroeconomic & Investment Newsletter, Mr. Heerdink states, “So far, it appears that the plan to cut corporate tax rates has led to a move…” Read full newsletter.

Companies Featured in December’s Newsletter:  Atossa Genetics, Inc. (NASDAQ: ATOS) | Fusion, Inc. (NASDAQ: FSNN) | Goldman Sachs (GS) | Health Insurance Innovations, Inc. (HIIQ) | Intel (INTC) & JPMorgan Chase (JPM).

Vista Partners publishes 100% of its content free. To receive free email updates from Vista’s extensive coverage universe, please sign up at VistaPGlobal.com/signup.

About Vista Partners LLC:

Founded in 2005, Vista Partners LLC (“Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, and Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.

Please follow Vista Partners on Twitter @VistaPResearch to receive updates, thoughts, and ideas on Dow 30 Components, Select Emerging Growth Companies & Vista’s Featured Companies.




Have You Read “Sunny Skies Ahead?” Vista Partners Weekly Market Update 12-23-17

Vista Partners has published  “Sunny Skies Ahead?” Vista Partners Weekly Market Update 12-23-17 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30 and Select Emerging Growth Companies.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” to Stay Informed! and to Stay Competitive!

It’s FREE & EASY to sign up.

Have a great weekend!